CRVS
Corvus Pharmaceuticals Inc
11.80$
-5.9%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -12.3% | -12.0% | +61.1% | -8.9% | +17.2% | -13.7% | +50.5% | -10.0% | -11.6% | +256.0% | -5.5% | |
| – | -15.5% | -18.3% | +111.2% | -11.1% | +26.8% | -16.4% | +66.6% | -11.7% | -13.0% | +312.2% | -7.9% | |
| – | -37.2% | -40.9% | +99.0% | -68.5% | +86.8% | -42.8% | +193.9% | -80.5% | +59.6% | +776.4% | -52.9% | |
| – | -15.6% | -18.5% | +113.5% | -11.8% | +24.8% | -14.9% | +68.3% | -11.7% | -13.6% | +317.1% | -9.1% | |
| – | +26.0% | -7.9% | +110.3% | +81.1% | -2.3% | +5.1% | +14.1% | +33.6% | +8.1% | +220.3% | +54.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -10.2% | -2.2% | +98.4% | +248.0% | -21.7% | -72.2% | -8.7% | -5.7% | +13.9% | +26.2% | +11.4% | |
| – | -5.9% | -2.2% | +98.4% | +248.0% | -23.7% | -73.8% | -8.3% | -5.1% | +16.2% | +29.1% | +12.9% | |
| – | +2.8% | -24.3% | -32.7% | -49.4% | -47.7% | +72.4% | +11.3% | +6.8% | +6.3% | +6.2% | +6.1% | |
| – | +8.6% | +5.5% | -24.6% | +54.4% | +37.9% | -49.3% | +139.8% | -37.1% | +26.2% | +88.6% | -13.8% | |
| – | -12.7% | -13.8% | +53.5% | -75.8% | +162.5% | +51.5% | +62.7% | -10.5% | -14.7% | +293.2% | -6.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.1% | +0.0% | +21.8% | +11.7% | +2.5% | +10.0% | +3.5% | +6.5% | -3.7% | +12.9% | +2.6% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.